SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with ...

Gastroparesis is a chronic disorder that affects a significant subset of the population. Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the only ...

September 9, 2009 — The FDA has approved metoclopramide 5- and 10-mg orally disintegrating tablets (Metozolv ODT, Salix Pharmaceuticals, Ltd) for the relief of symptoms associated with acute and ...

Evoke Pharma announced topline Phase 3 data demonstrating that treatment with EVK-001 for the symptomatic relief of acute and recurrent diabetic gastroparesis in adult women failed to achieve the ...

SOLANA BEACH, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...

Gimoti, a dopamine-2 (D2) antagonist, is a nasal spray formulation of metoclopramide. Gimoti™ (metoclopramide nasal spray; Evoke) is now available for the relief of symptoms in adults with acute and ...

SAN DIEGO, Jan. 22, 2014 -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study ...

Please provide your email address to receive an email when new articles are posted on . Recent study results suggest that nasal delivery of metoclopramide is effective for managing symptoms associated ...

Evoke Pharma, Inc. announced that it has received a Notice of Allowance from the USPTO for a patent application covering the use of its GIMOTI® (metoclopramide) nasal spray in patients with moderate ...

Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical office visits and related costs compared to oral metoclopramide SOLANA BEACH, Calif., Dec. 19, 2024 ...

SOLANA BEACH, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an ...

Evoke Pharma, Inc. announces its commitment to addressing the needs of patients with gastroparesis following the FDA's update indicating that the supply of unapproved domperidone, used internationally ...